KRAS/LKB1 co-mutant tumors have a higher activation of the hexosamine biosynthesis pathway (HBP), making them more dependent on the HBP enzyme glutamine-fructose-6-phosphate transaminase 2 (GFPT2) and defining a new metabolic vulnerability in such types of cancers (156). The gene discussed is GFPT2; the disease is cancer.